Auricular Bioelectronic Devices Market: Top Companies & Innovations

By /

Auricular Bioelectronic Devices Market Companies

  • NeuroSky, Inc.
  • Cala Health, Inc.
  • Bioness Inc.
  • Nurotron Bioelectronics
  • Medtronic plc
  • Abbott Laboratories
  • Cerbomed GmbH
  • Biovotion AG
  • Boston Scientific Corporation
  • Cyberonics (LivaNova)
  • SetPoint Medical
  • Neuros Medical, Inc.
  • Inspire Medical Systems
  • Otivio
  • ElectroCore, Inc.
  • Axonics Modulation Technologies
  • Valtronic SA
  • Earlogic Devices
  • Somavert Bioelectronics
  • NeuroSigma, Inc.

Get Sample Report

1. NeuroSky, Inc.

  • Company Name and Headquarters: NeuroSky, Inc. – San Jose, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: NeuroSky is known for its brain-computer interface (BCI) technologies, often integrated into headsets that rest on the forehead and earlobes to measure EEG signals. While not strictly “auricular” in the medical device sense, their technology uses ear contact for reference electrodes in some applications. Their main product is the MindWave Mobile, a headset that captures brainwave data. They also provide modules and SDKs for developers.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Difficult to estimate a specific “auricular bioelectronic device” market share as their primary focus is BCI technology. Their revenue is derived from sales of their MindWave products, modules, and licensing of their algorithms to various industries (education, gaming, wellness).

  • Recent Developments, Partnerships, or Innovations: Continuous refinement of their ThinkGear technology, expansion into educational and mental wellness applications. Partnerships with developers and researchers.

  • Competitive Positioning and Strategic Focus: Focuses on making BCI technology accessible and affordable for consumer and developer markets. Strong in research and development for non-invasive brainwave sensing.

  • Key Customers or Industries Served: Education, gaming, mental wellness apps, research institutions, consumer electronics developers.

2. Cala Health, Inc.

  • Company Name and Headquarters: Cala Health, Inc. – San Mateo, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Cala Health’s flagship product is Cala Trio™, a non-invasive prescription-only bioelectronic therapy for essential tremor. While the primary stimulating electrodes are worn on the wrist, the device incorporates auricular bioelectronic principles for personalized therapy delivery by measuring the tremor and then delivering customized electrical stimulation.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: As a relatively newer player in a specialized segment, their market share is growing. Revenue is primarily from sales of Cala Trio. Specific figures are not publicly disclosed, but they have secured significant funding.

  • Recent Developments, Partnerships, or Innovations: FDA clearance for Cala Trio, expanding insurance coverage, ongoing clinical trials to explore other indications.

  • Competitive Positioning and Strategic Focus: Pioneers in personalized, non-invasive neuromodulation for neurological conditions. Focus on evidence-based therapy and patient-centric design.

  • Key Customers or Industries Served: Patients with essential tremor, neurologists, movement disorder specialists.

3. Bioness Inc.

  • Company Name and Headquarters: Bioness Inc. – Valencia, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: While Bioness is primarily known for its functional electrical stimulation (FES) devices for foot drop and hand paralysis (e.g., L300 Go, H200 Wireless), they also explore neuromodulation techniques that could extend to auricular stimulation for various neurological conditions, though specific “auricular” devices are not their main commercial focus currently. Their general focus is on restoring function through electrical stimulation.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Minimal direct market share in a dedicated “auricular” segment. Revenue primarily from FES devices.

  • Recent Developments, Partnerships, or Innovations: Continued development of FES technologies, expanding indications, and improving connectivity and user experience for their existing devices.

  • Competitive Positioning and Strategic Focus: Leader in FES technology for rehabilitation. Focus on improving mobility and independence for individuals with neurological disorders.

  • Key Customers or Industries Served: Rehabilitation centers, physical therapists, occupational therapists, patients with stroke, multiple sclerosis, spinal cord injury, or traumatic brain injury.

4. Nurotron Bioelectronics

  • Company Name and Headquarters: Nurotron Bioelectronics Co., Ltd. – Hangzhou, China (with international presence)

  • Product Offerings related to Auricular Bioelectronic Devices: Nurotron is primarily known for its cochlear implant systems. While a cochlear implant is surgically implanted rather than “auricular” in the external sense, it is a bioelectronic device directly interfacing with the auditory system via the ear. They offer various cochlear implant models for different patient needs.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Significant player in the global cochlear implant market, particularly strong in Asia. Revenue is derived from cochlear implant sales and related services.

  • Recent Developments, Partnerships, or Innovations: Development of advanced speech processing strategies, smaller and more efficient implant designs, expansion into new markets.

  • Competitive Positioning and Strategic Focus: Aims to provide high-quality and affordable cochlear implant solutions, competing with global leaders like Cochlear and MED-EL.

  • Key Customers or Industries Served: ENT specialists, audiologists, patients with severe to profound hearing loss, particularly children and adults.

5. Medtronic plc

  • Company Name and Headquarters: Medtronic plc – Dublin, Ireland (Operational headquarters in Minneapolis, Minnesota, USA)

  • Product Offerings related to Auricular Bioelectronic Devices: Medtronic is a global leader in medical technology, including neuromodulation. While they don’t have many external auricular bioelectronic devices, their extensive portfolio includes implantable neuromodulation systems for various conditions. Their vagus nerve stimulation (VNS) systems (e.g., for epilepsy, depression) involve a lead that can be placed in the neck near the ear, though the device itself is implanted in the chest. They are also active in hearing solutions.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Medtronic holds a significant share in the broader neuromodulation market. Direct revenue from “auricular bioelectronic devices” as a distinct segment is not available, but their neuromodulation and hearing solutions contribute substantially to their overall revenue ($32.36 billion in FY23).

  • Recent Developments, Partnerships, or Innovations: Continuous innovation in neurostimulation for various neurological disorders, including deep brain stimulation (DBS), spinal cord stimulation (SCS), and VNS. Acquisition of various companies to expand their technology base.

  • Competitive Positioning and Strategic Focus: Global leader across multiple medical device segments, including neuromodulation. Focus on advanced therapies, data-driven healthcare, and expanding access to treatment.

  • Key Customers or Industries Served: Neurosurgeons, neurologists, cardiologists, pain management specialists, hospitals, and patients worldwide.

6. Abbott Laboratories

  • Company Name and Headquarters: Abbott Laboratories – Abbott Park, Illinois, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Abbott has a strong presence in neuromodulation, particularly with their spinal cord stimulation (SCS) and deep brain stimulation (DBS) systems. While not directly “auricular” in terms of external ear placement, they are major players in implantable bioelectronic devices for neurological conditions, some of which may have indirect applications or R&D in areas related to auricular nerves. They also have a significant diagnostics and diabetes care division.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Significant share in the broader neuromodulation market. Specific “auricular” segment revenue is not disclosed. Their total revenue was $40.0 billion in 2023.

  • Recent Developments, Partnerships, or Innovations: Introduction of new SCS and DBS systems with advanced features like MRI compatibility, extended battery life, and remote programming. Focus on patient comfort and improved therapeutic outcomes.

  • Competitive Positioning and Strategic Focus: Strong competitor in neuromodulation alongside Medtronic and Boston Scientific. Focus on integrated care, technological innovation, and expanding global reach.

  • Key Customers or Industries Served: Neurosurgeons, pain management specialists, neurologists, hospitals, and patients suffering from chronic pain, Parkinson’s disease, and essential tremor.

7. Cerbomed GmbH

  • Company Name and Headquarters: Cerbomed GmbH – Erlangen, Germany

  • Product Offerings related to Auricular Bioelectronic Devices: Cerbomed is specialized in non-invasive vagus nerve stimulation (nVNS) via the ear. Their key product is NEMOS®, a medical device designed for the treatment of epilepsy, depression, and chronic pain by stimulating the vagus nerve through the tragus of the ear.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Cerbomed is a niche player with a focused product. Their market share is specific to the non-invasive auricular VNS segment. Revenue is derived from NEMOS sales, primarily in Europe.

  • Recent Developments, Partnerships, or Innovations: Clinical trials for additional indications, expansion of distribution channels, refinement of their nVNS technology.

  • Competitive Positioning and Strategic Focus: Pioneer and leader in non-invasive auricular vagus nerve stimulation. Focus on developing evidence-based therapies for neurological and psychiatric disorders.

  • Key Customers or Industries Served: Neurologists, psychiatrists, pain specialists, hospitals, and patients with drug-resistant epilepsy, depression, or chronic pain.

8. Biovotion AG

  • Company Name and Headquarters: Biovotion AG – Zurich, Switzerland (now part of Biofourmis)

  • Product Offerings related to Auricular Bioelectronic Devices: Biovotion was known for its medical-grade wearable vital signs monitoring platforms, particularly a device worn on the upper arm. While not directly “auricular bioelectronic devices” in the therapeutic sense, their technology for continuous physiological monitoring could potentially be adapted for ear-based sensing if specific biomarkers or stimulation points were targeted there. Note: Biovotion was acquired by Biofourmis in 2020.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Prior to acquisition, market share was in the remote patient monitoring space. No specific “auricular” revenue.

  • Recent Developments, Partnerships, or Innovations: As part of Biofourmis, their technology contributes to Biofourmis’s broader remote patient monitoring and digital therapeutics platform.

  • Competitive Positioning and Strategic Focus: Under Biofourmis, the focus is on AI-powered digital therapeutics and remote patient monitoring to manage chronic conditions and prevent acute exacerbations.

  • Key Customers or Industries Served: Healthcare providers, pharmaceutical companies, clinical researchers, patients in remote monitoring programs.

9. Boston Scientific Corporation

  • Company Name and Headquarters: Boston Scientific Corporation – Marlborough, Massachusetts, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Boston Scientific is a major player in neuromodulation, offering spinal cord stimulation (SCS) and deep brain stimulation (DBS) systems for chronic pain, Parkinson’s disease, and essential tremor. Similar to Medtronic and Abbott, while their primary devices are not “auricular” in the external ear sense, they are key developers of implantable bioelectronic devices that manage neurological conditions, and their R&D may touch on vagal or cranial nerve stimulation.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Significant share in the broader neuromodulation market. No specific “auricular” segment revenue. Total revenue was $14.24 billion in 2023.

  • Recent Developments, Partnerships, or Innovations: Development of advanced SCS systems (e.g., WaveWriter Alpha™ with combination therapy), acquisition of new technologies to expand their portfolio in peripheral nerve stimulation and other areas.

  • Competitive Positioning and Strategic Focus: Strong competitor in neuromodulation. Focus on patient-specific therapies, expanded indications, and improving clinical outcomes through innovative device features.

  • Key Customers or Industries Served: Neurosurgeons, pain management specialists, neurologists, hospitals, and patients with chronic pain or movement disorders.

10. Cyberonics (LivaNova)

  • Company Name and Headquarters: Cyberonics (now part of LivaNova PLC) – London, UK (Operational headquarters in Houston, Texas, USA)

  • Product Offerings related to Auricular Bioelectronic Devices: Cyberonics was a pioneer and a leading provider of vagus nerve stimulation (VNS) therapy for epilepsy and treatment-resistant depression. Their VNS systems involve an implantable device in the chest with a lead wrapped around the vagus nerve in the neck. While not externally auricular, it directly targets a cranial nerve that has connections and influence over a wide range of body functions. LivaNova continues to innovate in this space.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: LivaNova holds a significant share in the implantable VNS market. Specific revenue for this segment is part of LivaNova’s broader Neuromodulation division.

  • Recent Developments, Partnerships, or Innovations: Development of next-generation VNS systems with advanced features like auto-stimulation, more refined therapy delivery, and improved patient monitoring. Expansion into new geographic markets.

  • Competitive Positioning and Strategic Focus: Leader in implantable VNS therapy. Focus on improving outcomes for patients with drug-resistant epilepsy and depression, and exploring new applications for VNS.

  • Key Customers or Industries Served: Neurologists, neurosurgeons, psychiatrists, hospitals, and patients with refractory epilepsy or treatment-resistant depression.

11. SetPoint Medical

  • Company Name and Headquarters: SetPoint Medical – Valencia, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: SetPoint Medical is developing an investigational bioelectronic device that provides vagus nerve stimulation (VNS) for autoimmune diseases like rheumatoid arthritis and Crohn’s disease. Their device is implanted, targeting the vagus nerve in the neck, similar to epilepsy VNS devices. While the device is internal, the therapy leverages the broad immunomodulatory effects of the vagus nerve, which originates from the brainstem near the auricular region.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: As a company with an investigational device, they do not have commercial market share or revenue yet. They have secured significant venture funding.

  • Recent Developments, Partnerships, or Innovations: Positive results from clinical trials for rheumatoid arthritis and Crohn’s disease, FDA Breakthrough Device Designation for rheumatoid arthritis, ongoing research.

  • Competitive Positioning and Strategic Focus: Pioneer in bioelectronic medicine for autoimmune diseases. Focus on developing a novel, drug-free therapy to address chronic inflammatory conditions.

  • Key Customers or Industries Served: Rheumatologists, gastroenterologists, immunologists, and patients with autoimmune diseases.

12. Neuros Medical, Inc.

  • Company Name and Headquarters: Neuros Medical, Inc. – Aliso Viejo, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Neuros Medical is developing the Altius® System, an implantable nerve block technology for the treatment of chronic neuropathic pain (e.g., post-amputation pain). While it targets peripheral nerves, their focus on nerve modulation for pain could potentially extend to cranial or auricular nerves in future applications, though their current commercial focus is elsewhere.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Pre-commercial stage for their primary product. No specific “auricular” market share or revenue.

  • Recent Developments, Partnerships, or Innovations: Clinical trials for the Altius System, FDA Breakthrough Device Designation, ongoing R&D.

  • Competitive Positioning and Strategic Focus: Developing a unique high-frequency nerve block technology for severe, intractable neuropathic pain, aiming to provide a non-opioid solution.

  • Key Customers or Industries Served: Pain management specialists, neurosurgeons, and patients with chronic intractable neuropathic pain.

13. Inspire Medical Systems

  • Company Name and Headquarters: Inspire Medical Systems, Inc. – Golden Valley, Minnesota, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Inspire Medical Systems is known for its Inspire® Upper Airway Stimulation (UAS) therapy for obstructive sleep apnea (OSA). This is an implantable device that monitors breathing and delivers mild stimulation to the hypoglossal nerve (a cranial nerve) to keep the airway open during sleep. While the lead is placed on the hypoglossal nerve, the device is implantable and relates to cranial nerve stimulation, which is a broader category that can include auricular stimulation research.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Inspire is the leader in hypoglossal nerve stimulation for OSA. Their revenue is growing rapidly from the adoption of Inspire therapy. Specific “auricular” revenue is not applicable.

  • Recent Developments, Partnerships, or Innovations: Expanding indications, improving device features, expanding geographic reach, and growing awareness among patients and physicians.

  • Competitive Positioning and Strategic Focus: Pioneer and market leader in implantable therapy for OSA. Focus on providing a clinically proven alternative to CPAP for suitable patients.

  • Key Customers or Industries Served: ENT specialists, sleep medicine specialists, pulmonologists, and patients with moderate to severe OSA.

14. Otivio AS

  • Company Name and Headquarters: Otivio AS – Oslo, Norway

  • Product Offerings related to Auricular Bioelectronic Devices: Otivio develops the Otivio Flow device, which uses electrical stimulation to improve blood circulation in the legs, primarily for patients with peripheral artery disease (PAD) and diabetic foot ulcers. The device is worn on the calf; however, their foundational research and intellectual property may extend to other forms of bioelectric stimulation, potentially including auricular applications for nerve or circulatory conditions.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Niche player in circulatory bioelectronic devices. No specific “auricular” market share or revenue.

  • Recent Developments, Partnerships, or Innovations: Clinical trials demonstrating efficacy in improving circulation and wound healing, expansion into new markets in Europe.

  • Competitive Positioning and Strategic Focus: Focus on non-invasive bioelectric solutions for vascular conditions.

  • Key Customers or Industries Served: Vascular surgeons, diabetologists, wound care clinics, and patients with PAD or diabetic foot ulcers.

15. ElectroCore, Inc.

  • Company Name and Headquarters: ElectroCore, Inc. – Basking Ridge, New Jersey, USA

  • Product Offerings related to Auricular Bioelectronic Devices: ElectroCore is a leader in non-invasive vagus nerve stimulation (nVNS) with their product gammaCore®. This handheld device is placed on the neck over the vagus nerve and is FDA-cleared for the acute and preventive treatment of cluster headache and migraine. While it’s cervical rather than auricular, it’s a prominent non-invasive VNS device in the broader neuromodulation market and could be seen as a direct competitor to auricular VNS devices for headache.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Significant player in the non-invasive VNS market for headache disorders. Revenue is primarily from gammaCore sales.

  • Recent Developments, Partnerships, or Innovations: Expanding indications, securing additional insurance coverage, developing new generations of the device.

  • Competitive Positioning and Strategic Focus: Leader in non-invasive cervical VNS for primary headache disorders. Focus on providing a drug-free, non-invasive treatment option.

  • Key Customers or Industries Served: Neurologists, headache specialists, primary care physicians, and patients with migraine or cluster headache.

16. Axonics Modulation Technologies

  • Company Name and Headquarters: Axonics Modulation Technologies, Inc. – Irvine, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: Axonics is a fast-growing company focused on sacral neuromodulation (SNM) for bladder and bowel dysfunction. Their Axonics Therapy system is an implantable device that stimulates the sacral nerves. While SNM is not auricular, it falls under the broader category of neuromodulation using implantable bioelectronic devices.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Rapidly gaining market share in the SNM segment, competing with Medtronic. No specific “auricular” market share or revenue.

  • Recent Developments, Partnerships, or Innovations: FDA approval for their SNM system, continuous improvement in battery life and MRI compatibility, strong sales growth, and expansion into new markets.

  • Competitive Positioning and Strategic Focus: Disrupting the SNM market with a smaller, longer-lasting, and full-body MRI-conditional system. Focus on improving patient quality of life and clinician ease of use.

  • Key Customers or Industries Served: Urologists, urogynecologists, colorectal surgeons, and patients with overactive bladder, urinary retention, or fecal incontinence.

17. Valtronic SA

  • Company Name and Headquarters: Valtronic SA – Les Charbonnières, Switzerland (with global facilities)

  • Product Offerings related to Auricular Bioelectronic Devices: Valtronic is an original design manufacturer (ODM) and electronic manufacturing services (EMS) provider specializing in miniaturized and implantable electronic solutions for medical devices. They don’t have their own “auricular bioelectronic devices” as products but serve as a critical supplier and development partner for companies that do create such devices. This could include manufacturing components for hearing aids, cochlear implants, or other implantable neurostimulation devices that have an auricular interface or application.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: As a B2B supplier, their market share is indirect. Revenue comes from contracts with various medical device companies, some of whom operate in the auricular space.

  • Recent Developments, Partnerships, or Innovations: Continuous investment in miniaturization technologies, advanced manufacturing processes, and compliance with strict medical device regulations. Partnerships with leading medical technology companies.

  • Competitive Positioning and Strategic Focus: High-precision manufacturing and design for complex, miniaturized, and implantable medical electronics.

  • Key Customers or Industries Served: Medical device companies, especially those in neuromodulation, diagnostics, and implantable therapies.

18. Earlogic Devices

  • Company Name and Headquarters: Information on a distinct “Earlogic Devices” as a major player in auricular bioelectronic devices is not readily available in public databases or market reports as a standalone entity with significant market presence. It’s possible this is a very small startup, a research project, or a brand name under a larger company.

  • Product Offerings related to Auricular Bioelectronic Devices: Without specific company details, it’s difficult to list product offerings.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Unknown; likely negligible or non-existent as a distinct commercial entity.

  • Recent Developments, Partnerships, or Innovations: Unknown.

  • Competitive Positioning and Strategic Focus: Unknown.

  • Key Customers or Industries Served: Unknown.

19. Somavert Bioelectronics

  • Company Name and Headquarters: Information on a distinct “Somavert Bioelectronics” as a major player in auricular bioelectronic devices is not readily available in public databases or market reports. “Somavert” is primarily associated with a pharmaceutical drug for acromegaly, not a bioelectronics company. It’s possible this is a misspelling, a very new or obscure startup, or a non-existent entity in the bioelectronics market.

  • Product Offerings related to Auricular Bioelectronic Devices: Without specific company details, it’s difficult to list product offerings.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: Unknown; likely negligible or non-existent as a distinct commercial entity.

  • Recent Developments, Partnerships, or Innovations: Unknown.

  • Competitive Positioning and Strategic Focus: Unknown.

  • Key Customers or Industries Served: Unknown.

20. NeuroSigma, Inc.

  • Company Name and Headquarters: NeuroSigma, Inc. – Los Angeles, California, USA

  • Product Offerings related to Auricular Bioelectronic Devices: NeuroSigma is a bioelectronic medicine company focused on trigeminal nerve stimulation (TNS). Their flagship product is the Monarch® eTNS™ System, which is the first non-invasive, prescription-only device cleared by the FDA for the treatment of ADHD in pediatric patients. The device is worn on the forehead and delivers mild electrical stimulation to branches of the trigeminal nerve. While the device is worn on the forehead, the trigeminal nerve has sensory branches around the ear, and the general principle of cranial nerve stimulation (similar to VNS) is highly relevant to auricular bioelectronics.

  • Market Share and Estimated Revenue from Auricular Bioelectronic Devices Segment: As a niche player, their market share is specific to eTNS for ADHD. Revenue is derived from Monarch eTNS sales.

  • Recent Developments, Partnerships, or Innovations: FDA clearance for pediatric ADHD, ongoing research into other indications (e.g., depression, epilepsy), expanding clinical adoption.

  • Competitive Positioning and Strategic Focus: Pioneer in external trigeminal nerve stimulation. Focus on providing a non-drug, non-invasive therapy for neurological and psychiatric disorders.

  • Key Customers or Industries Served: Child psychiatrists, neurologists, pediatricians, and pediatric patients with ADHD.

Contact Us

Related Posts

Scroll to Top